Newsletter Subject

EPA Scientists Say They Were Pressured to Downplay Health Harms From Chemicals

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Sat, Sep 28, 2024 11:14 AM

Email Preheader Text

Weekly Review Saturday, September 28, 2024 THE BREAK ROOM CME SPOTLIGHT THE BREAK ROOM ADVERTISEMENT

[MEDPAGE TODAY]( Weekly Review Saturday, September 28, 2024 [EPA Scientists Say They Were Pressured to Downplay Health Harms From Chemicals]( [Florida's New COVID Booster Guidance Is Straight-Up Misinformation, Experts Say]( [Accused Doc: 'People Are Liars'; Hospital Settles Over Leaked Nude Patient Photos]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Exploring HER2 Targeting: Transforming Treatment for Metastatic and Locally Advanced HER2+ Cancers]( [Flavonoid-Dementia Link; Political Beliefs and the Brain; Ethics of Brain Biopsies]( [Can Exercise Bring on Rhabdomyolysis?]( THE BREAK ROOM [Play Today's Wordosis: Our Medical Word Game]( ADVERTISEMENT [Ob/Gyn Accused of Catfishing Women]( CME SPOTLIGHT [Precision Targeting in Acute Myeloid Leukemia: Optimizing Disease-Informed, Patient-Centered Care]( [High ADHD Medication Doses Tied to Psychosis; Rapid Tests for Malaria]( [Tragus Stimulation for High BP; House Passes HEARTS Act; Risk in Pregnancy Surrogacy]( [Psilocybin vs Lexapro; FDA's KarXT Decision Nears; Obesity and Schizophrenia]( CME SPOTLIGHT [Novel and Emerging Treatments for HR+/HER2- Breast Cancer]( [Training on Cadavers Still Essential for Medical Students]( [NIH Neuroscience Leader Committed Research Misconduct, Agency Says]( [Prolonged Symptoms After Lyme Disease: What CDC Wants Doctors to Know]( CME SPOTLIGHT [Breakthrough Immunotherapies Transforming Early-Stage NSCLC Treatment]( [MedPod Today: New COVID Variant; FDA Eye Drop Warning; CRNA Scope Creep?]( [One in Three Former NFL Players Believe They Have CTE]( [First-Ever Biologic Approved for COPD]( CME SPOTLIGHT [Harnessing the Power of Immuno-Modulating Vaccines in Cancer Treatment]( [Senators Tangle Over Impact of Dobbs Abortion Decision]( [Healthcare's Post-Traumatic Growth]( [UVA Med School Faces Toxic Work Environment Allegations]( CME SPOTLIGHT [Optimizing Use of PARP Inhibitors in Early-Stage and Metastatic Breast Cancer Patients With DNA Damage Repair Pathway Mutations]( [Sexual and Gender Minorities More Likely to Have Adverse Brain Outcomes]( [Abortion Clinics -- And Patients -- Are on the Move, as State Laws Keep Shifting]( [One-Year CGM Cleared; Osteoporosis Lawsuits Revived; Chemicals and Early Puberty]( CME SPOTLIGHT [Changing Inertia in Chronic Myeloid Leukemia Management: Key Strategies From Leading Experts]( [The Data Are Clear: Patients Regain Weight After Stopping GLP-1 Drugs]( [CDC Alerts on Mpox Prevention for Patients Heading to Areas With Clade I Outbreaks]( [Gamification Offers Youth Some Benefit in ADHD, Depression]( CME SPOTLIGHT [Decoding Complex Chronic Lymphocytic Leukemia Cases: An Expert TheraTalk]( [Zachary Quinto Steps Into Giant-Sized Doctor's Shoes in NBC's 'Brilliant Minds']( [FDA Approves First Novel Drug for Schizophrenia in Decades]( ['Do a Real Study, Then We Can Talk': What We Heard This Week]( [Women With MS Less Likely to Receive Treatment Than Men]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_DHE_Weekly?xid=nl_mpt_DHE_2024-09-28&mh=3c4cdd242849aa0e970f25e401732f81) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.